AT7687
Asset
Blocks the glucose-dependent insulinotropic polypeptide receptor to treat obesity.
- Stage
- Phase 1
- Modality
- Peptide
- Target
- GIPR
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Obesity
Phase 1, doi.org, 7 Jun 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets2
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.